Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:chemicalFormula |
store in a cool, dry place
handle with care stable under normal conditions therapeutic agent C20H24N2O2 regulated substance phenylpiperazine |
| gptkbp:clinicalTrials |
gptkb:USA
Europe Phase II promising effective well tolerated |
| gptkbp:compatibleWith |
high
|
| gptkbp:composedOf |
chemical synthesis
|
| gptkbp:contraindication |
insomnia
weight gain sexual dysfunction |
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| https://www.w3.org/2000/01/rdf-schema#label |
WLR-676
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:marketSegment |
not marketed
|
| gptkbp:numberOfStudents |
12 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:origin |
(2S)-2-(4-(4-(dimethylamino)phenyl)-1-piperazinyl)-1-(2-methoxyphenyl)ethanol
|
| gptkbp:patentAssignee |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:patentStatus |
patented
|
| gptkbp:productionCompany |
clinical trials
|
| gptkbp:relatedPatent |
WLR-675
WLR-677 |
| gptkbp:releaseYear |
2005
high-throughput screening |
| gptkbp:research |
government grants
private investors |
| gptkbp:researchFocus |
mental health
depression anxiety disorders |
| gptkbp:researchInterest |
gptkb:ABC_Pharmaceuticals
gptkb:XYZ_University international collaboration published in peer-reviewed journals clinical trial reports |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally safe
|
| gptkbp:sideEffect |
dizziness
nausea dry mouth |
| gptkbp:targets |
adults
adolescents serotonin receptor |
| gptkbp:triggerType |
serotonin reuptake inhibitor
|
| gptkbp:uses |
antidepressant
|
| gptkbp:weight |
324.42 g/mol
|